Acurate Neo (system of implantation of the aortal valve)

2020: The announcement of Acurate Neo - the system of implantation of the aortal valve

At the end of September, 2020 Boston Scientific provided the new device for transkateterny implantation of the aortal valve (TAVI). The solution is available in Europe, the producer reported.

The valve Acurate Neo 2 system is intended for recovery of a normal blood-groove through strongly narrowed aortal valve and differs in the new technology of a ring seal developed taking into account the calcinated vessel walls thanks to what minimizes a paravalve regurgitation. Regulatory bodies approved use of the valve Acurate Neo 2 system according to expanded indications at patients with an aorta stenosis who are considered as suitable candidates for cardiac interventions regardless of age or risk level.

Boston Scientific released the system of implantation of the aortal valve for patients of any age

We consider that emergence in the market of this differentiated valve with the improved system of consolidation will improve clinical outcomes and will help to develop new devices, - the president of department of intervention cardiology of Boston Scientific Joe Fitzgerald noted. - The valve Acurate Neo 2 system naturally continues a line of our products, the including system of replacement of the aortal Lotus Edge valve and the SENTINEL system for protection of a brain against a trombotichesky stroke and by that meets requirements of a broad spectrum of patients.

Boston Scientific reported that, according to the research Acurate Neo 2 CE-Mark, the paravalve regurgitation was not observed or observed only in easy degree at 97% and 97.5% of patients in 30 days and 1 year after implantation, respectively. At 3.0% and 2.5% of patients the moderate paravalve regurgitation was observed, and cases of a heavy regurgitation were not noted.

For September, 2020 the device was not approved yet by regulatory bodies of the USA and passed clinical trial of ACURATE IDE.^[1]

Notes